(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Brilliant Acquisition Corporation, Ebix, and Bellicum Pharmaceuticals.

The three biggest losers today are ContraFect Corporation, Nikola, and CSI Compressco LP.

Winners today

1. Brilliant Acquisition Corporation (BRLI) – 25.28%

Brilliant Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2019 and is based in Shanghai, China.

NASDAQ ended the session with Brilliant Acquisition Corporation rising 25.28% to $11.25 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Brilliant Acquisition Corporation has a trailing twelve months EPS of $-0.25.

Volume

Today’s last reported volume for Brilliant Acquisition Corporation is 165113 which is 2256.73% above its average volume of 7006.

More news about Brilliant Acquisition Corporation.

2. Ebix (EBIX) – 12.98%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix jumping 12.98% to $4.53 on Friday while NASDAQ rose 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $0.16.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 28.28. Meaning, the purchaser of the share is investing $28.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.49%.

More news about Ebix.

3. Bellicum Pharmaceuticals (BLCM) – 12.37%

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

NASDAQ ended the session with Bellicum Pharmaceuticals rising 12.37% to $0.22 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Bellicum Pharmaceuticals has a trailing twelve months EPS of $-0.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -148.5%.

Moving Average

Bellicum Pharmaceuticals’s worth is above its 50-day moving average of $0.21 and way under its 200-day moving average of $0.40.

More news about Bellicum Pharmaceuticals.

4. CASI Pharmaceuticals (CASI) – 11.74%

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

NASDAQ ended the session with CASI Pharmaceuticals jumping 11.74% to $6.66 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, CASI Pharmaceuticals has a trailing twelve months EPS of $-3.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.42%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 13.5%, now sitting on 42.26M for the twelve trailing months.

Moving Average

CASI Pharmaceuticals’s value is way above its 50-day moving average of $3.91 and way above its 200-day moving average of $2.78.

Sales Growth

CASI Pharmaceuticals’s sales growth is negative 38.3% for the current quarter and 43.8% for the next.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 87.1% and 88.9%, respectively.

More news about CASI Pharmaceuticals.

5. bluebird bio (BLUE) – 11.55%

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with bluebird bio jumping 11.55% to $4.83 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, bluebird bio has a trailing twelve months EPS of $-0.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.81%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 263.2% and a negative 261.9%, respectively.

Volume

Today’s last reported volume for bluebird bio is 6371860 which is 69.95% above its average volume of 3749080.

More news about bluebird bio.

6. Consumer Portfolio Services (CPSS) – 9.49%

Consumer Portfolio Services, Inc. operates as a specialty finance company in the United States. It purchases and services retail automobile contracts originated by franchised automobile dealers and select independent dealers in the sale of new and used automobiles, light trucks, and passenger vans. The company, through its automobile contract purchases, offers indirect financing to the customers of dealers with limited credit histories or past credit problems. It serves as an alternative source of financing for dealers, facilitating sales to customers who might not be able to obtain financing from commercial banks, credit unions, and the captive finance companies. The company also acquires installment purchase contracts in four merger and acquisition transactions; and offers financing directly to sub-prime consumers to facilitate their purchase of a new or used automobile, light truck, or passenger van. The company services its automobile contracts through its branches in California, Nevada, Virginia, Florida, and Illinois. Consumer Portfolio Services, Inc. was founded in 1991 and is based in Las Vegas, Nevada.

NASDAQ ended the session with Consumer Portfolio Services rising 9.49% to $8.88 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Consumer Portfolio Services has a trailing twelve months EPS of $2.13.

PE Ratio

Consumer Portfolio Services has a trailing twelve months price to earnings ratio of 4.17. Meaning, the purchaser of the share is investing $4.17 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.6%.

Moving Average

Consumer Portfolio Services’s worth is below its 50-day moving average of $9.23 and way below its 200-day moving average of $10.24.

Revenue Growth

Year-on-year quarterly revenue growth declined by 22.5%, now sitting on 226.16M for the twelve trailing months.

More news about Consumer Portfolio Services.

7. LendingTree (TREE) – 8.8%

LendingTree, Inc., through its subsidiary, LT Intermediate Company, LLC, operates online consumer platform in the United States. It operates through three segments: Home, Consumer, and Insurance. The Home segment offers purchase mortgage, refinance mortgage, reverse mortgage, and home equity loans; lines of credit; and real estate brokerage services. The Consumer segment provides credit cards; personal, small business, student, and auto loans; deposit accounts; and other credit products, such as credit repair and debt settlement services. The Insurance segment includes information, tools, and access to insurance quote products, including home and automobile, through which consumers are matched with insurance lead aggregators to obtain insurance offers. In addition, the company offers QuoteWizard.com, a marketplace for insurance comparison; ValuePenguin, a personal finance website that offers consumers objective analysis on various financial topics from insurance to credit cards; and Stash, a consumer investing and banking platform that offers a suite of personal investment accounts, traditional and Roth IRAs, custodial investment accounts, and banking services, including checking accounts and debit cards with a Stock-Back rewards program. The company was formerly known as Tree.com, Inc. and changed its name to LendingTree, Inc. in January 2015. LendingTree, Inc. was incorporated in 1996 and is based in Charlotte, North Carolina.

NASDAQ ended the session with LendingTree jumping 8.8% to $22.75 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, LendingTree has a trailing twelve months EPS of $-11.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -94.15%.

More news about LendingTree.

8. DISH Network (DISH) – 8.59%

DISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. The company also provides access to movies and television shows through TV or Internet-connected devices; and dishanywhere.com and mobile applications on Internet-connected devices to view authorized content, search program listings, and remotely control certain features of their DVRs. In addition, it offers Sling TV services, including Sling domestic, Sling International, Sling Latino, Sling Orange, and Sling Blue services that require an internet connection and are available on streaming-capable devices, such as streaming media devices, TVs, tablets, computers, game consoles, and phones, as well as market SLING TV services to consumers who do not subscribe to traditional satellite and cable pay-TV services. Further, the company provides wireless subscribers consumer plans with no annual service contracts, as well as monthly service plans, including high-speed data and unlimited talk and text. The company offers receiver systems and programming through direct sales channels, as well as independent third parties, such as small retailers, direct marketing groups, local and regional consumer electronics stores, retailers, and telecommunications companies. DISH Network Corporation was founded in 1980 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with DISH Network jumping 8.59% to $4.30 on Friday, following the last session’s upward trend. NASDAQ jumped 1.37% to $14,339.99, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, DISH Network has a trailing twelve months EPS of $1.9.

PE Ratio

DISH Network has a trailing twelve months price to earnings ratio of 2.26. Meaning, the purchaser of the share is investing $2.26 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.19%.

Sales Growth

DISH Network’s sales growth is negative 7.7% for the present quarter and negative 3.8% for the next.

More news about DISH Network.

9. Walgreens Boots (WBA) – 8.5%

Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.

NASDAQ ended the session with Walgreens Boots rising 8.5% to $23.20 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Walgreens Boots has a trailing twelve months EPS of $-3.57.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.98%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 139.08B for the twelve trailing months.

Moving Average

Walgreens Boots’s worth is above its 50-day moving average of $21.44 and way under its 200-day moving average of $28.53.

More news about Walgreens Boots.

10. AMD (AMD) – 8.15%

Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. It operates in four segments: Data Center, Client, Gaming, and Embedded segments. The company offers x86 microprocessors and graphics processing units (GPUs) as an accelerated processing unit, chipsets, data center, and professional GPUs; and embedded processors, and semi-custom system-on-chip (SoC) products, microprocessor and SoC development services and technology, data processing unites, field programmable gate arrays (FPGA), and adaptive SoC products. It also provides processors under the AMD Ryzen, AMD Ryzen PRO, Ryzen Threadripper, Ryzen Threadripper PRO, AMD Athlon, AMD Athlon PRO, and AMD PRO A-Series brand names; graphics under the AMD Radeon graphics and AMD Embedded Radeon graphics; and professional graphics under the AMD Radeon Pro graphics brand name. In addition, the company offers data center graphics under the Radeon Instinct and Radeon PRO V-series brands, as well as servers under the AMD Instinct accelerators brand; server microprocessors under the AMD EPYC brands; embedded processor solutions under the AMD Athlon, AMD Geode, AMD Ryzen, AMD EPYC, AMD R-Series, and G-Series brands; FPGA products under the Virtex-6, Virtex-7, Virtex UltraScale+, Kintex-7, Kintex UltraScale, Kintex UltraScale+, Artix-7, Artix UltraScale+, Spartan-6, and Spartan-7 brands; adaptive SOCs under the Zynq-7000, Zynq UltraScale+ MPSoC, Zynq UltraScale+ RFSoCs, Versal HBM, Versal Premium, Versal Prime, Versal AI Core, Versal AI Edge, Vitis, and Vivado brands; and compute and network acceleration board products under the Alveo brand. It serves original equipment and design manufacturers, public cloud service providers, system integrators, independent distributors, online and brick and mortar retailers, and add-in-board manufacturers through its direct sales force, independent distributors, and sales representatives. The company was incorporated in 1969 and is headquartered in Santa Clara, California.

NASDAQ ended the session with AMD rising 8.15% to $126.33 on Friday, after three successive sessions in a row of losses. NASDAQ rose 1.37% to $14,339.99, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, AMD has a trailing twelve months EPS of $0.11.

PE Ratio

AMD has a trailing twelve months price to earnings ratio of 1148.5. Meaning, the purchaser of the share is investing $1148.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.38%.

Previous days news about AMD

• AMD strengthens portfolio with new AI & data center products. According to Zacks on Thursday, 7 December, "The latest Ryzen 8040 series is based on AMD Zen 4 processor architecture and supports advanced LPDDR5 memory. ", "Dell recently demonstrated its PowerEdge XE9680 server that features eight AMD Instinct MI300 series accelerators and the new Dell Validated Design for Generative AI with AMD ROCm-powered AI frameworks.AMD, along with its partners, continues to offer solutions that enable greater data center consolidation. "

More news about AMD.

Losers Today

1. ContraFect Corporation (CFRX) – -27.95%

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

NASDAQ ended the session with ContraFect Corporation falling 27.95% to $0.05 on Friday while NASDAQ rose 1.37% to $14,339.99.

Earnings Per Share

As for profitability, ContraFect Corporation has a trailing twelve months EPS of $-10.83.

Moving Average

ContraFect Corporation’s worth is way below its 50-day moving average of $0.26 and way under its 200-day moving average of $1.13.

More news about ContraFect Corporation.

2. Nikola (NKLA) – -17.57%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola falling 17.57% to $0.81 on Friday, following the last session’s upward trend. NASDAQ rose 1.37% to $14,339.99, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -159.83%.

More news about Nikola.

3. CSI Compressco LP (CCLP) – -10.88%

CSI Compressco LP provides contract services for natural gas compression and treating in the United States, Latin America, Canada, Egypt, and internationally. The company offers natural gas compression services through low-, medium-, and high-horsepower compressor packages for oil and natural gas production, gathering, artificial lift, transmission, processing, and storage. It also provides treating services for natural gas producers and midstream companies, such as providing equipment for lease or sale, equipment installation services, and the operation of equipment for removal of contaminants from a natural gas stream, and natural gas cooling to reduce the temperature of produced gas and liquids; well monitoring and sand separation services; and operation, maintenance, overhaul, and reconfiguration services for compression equipment. In addition, the company sells engine parts, compressor package parts, and other parts manufactured by third-party suppliers. CSI Compressco GP LLC serves as the general partner of CSI Compressco LP. The company was formerly known as Compressco Partners, L.P. and changed its name to CSI Compressco LP in December 2014. CSI Compressco LP was incorporated in 2008 and is headquartered in The Woodlands, Texas.

NASDAQ ended the session with CSI Compressco LP sliding 10.88% to $1.72 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, CSI Compressco LP has a trailing twelve months EPS of $-0.08.

Yearly Top and Bottom Value

CSI Compressco LP’s stock is valued at $1.72 at 01:32 EST, way under its 52-week high of $2.06 and way above its 52-week low of $1.04.

More news about CSI Compressco LP.

4. Cutera (CUTR) – -6.46%

Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, myQ, and skincare products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera.com. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1988 and is headquartered in Brisbane, California.

NASDAQ ended the session with Cutera falling 6.46% to $2.25 on Friday while NASDAQ rose 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Cutera has a trailing twelve months EPS of $-3.86.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 233.3% and a negative 780%, respectively.

More news about Cutera.

5. NeuroMetrix (NURO) – -6.18%

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix sliding 6.18% to $3.49 on Friday, following the last session’s upward trend. NASDAQ rose 1.37% to $14,339.99, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-5.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.61%.

More news about NeuroMetrix.

6. Bionano Genomics (BNGO) – -5.99%

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

NASDAQ ended the session with Bionano Genomics sliding 5.99% to $1.57 on Friday, following the last session’s upward trend. NASDAQ rose 1.37% to $14,339.99, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-7.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.43%.

Sales Growth

Bionano Genomics’s sales growth is 28.3% for the present quarter and 46.5% for the next.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 33.1% and 37.5%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 29%, now sitting on 33.61M for the twelve trailing months.

Volatility

Bionano Genomics’s last week, last month’s, and last quarter’s current intraday variation average was 1.25%, 0.86%, and 5.03%.

Bionano Genomics’s highest amplitude of average volatility was 7.31% (last week), 4.97% (last month), and 5.03% (last quarter).

More news about Bionano Genomics.

7. Beyond Meat (BYND) – -5.75%

Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club, convenience, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.

NASDAQ ended the session with Beyond Meat sliding 5.75% to $9.10 on Friday while NASDAQ rose 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Beyond Meat has a trailing twelve months EPS of $-3.89.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 16.2% and 13%, respectively.

More news about Beyond Meat.

8. Canaan (CAN) – -4.81%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan sliding 4.81% to $1.49 on Friday, following the last session’s upward trend. NASDAQ rose 1.37% to $14,339.99, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.

Moving Average

Canaan’s value is way under its 50-day moving average of $1.78 and way below its 200-day moving average of $2.31.

Volatility

Canaan’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.85%, a negative 0.98%, and a positive 3.63%.

Canaan’s highest amplitude of average volatility was 7.30% (last week), 5.05% (last month), and 3.63% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 75.1%, now sitting on 160.89M for the twelve trailing months.

Yearly Top and Bottom Value

Canaan’s stock is valued at $1.49 at 01:32 EST, way below its 52-week high of $3.98 and higher than its 52-week low of $1.44.

More news about Canaan.

9. ClearOne (CLRO) – -4.75%

ClearOne, Inc., together with its subsidiaries, designs, develops, and sells conferencing, collaboration, and network streaming solutions for voice and visual communications in the United States and internationally. The company offers a range of audio conferencing products, including professional audio conferencing and sound-reinforcement products for use in enterprise, healthcare, education and distance learning, government, legal, and finance organizations; mid-tier premium conferencing products for smaller rooms, and small and medium businesses, which interface with video and Web conferencing systems; USB-based personal and group speakerphones that could be used with PCs, laptops, tablets, smartphones, and other portable devices; and traditional tabletop conferencing phones used in conference rooms and offices. It also provides video products, such as video conferencing and collaboration solutions; and AV networking, which deliver the IP A/V experience by streaming time sensitive high definition audio and video, and control over TCP/IP networks. In addition, the company offers professional microphones consisting of beamforming microphones, ceiling microphones, and wireless microphones. ClearOne, Inc. sells its commercial products to a network of independent professional audiovisual, information technology, and telecommunications distributors, as well as systems integrators, dealers, value-added resellers, and end-users. The company was incorporated in 1983 and is headquartered in Salt Lake City, Utah.

NASDAQ ended the session with ClearOne falling 4.75% to $0.78 on Friday while NASDAQ jumped 1.37% to $14,339.99.

Earnings Per Share

As for profitability, ClearOne has a trailing twelve months EPS of $0.85.

PE Ratio

ClearOne has a trailing twelve months price to earnings ratio of 0.92. Meaning, the purchaser of the share is investing $0.92 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.23%.

Moving Average

ClearOne’s value is above its 50-day moving average of $0.73 and way below its 200-day moving average of $1.06.

More news about ClearOne.

10. Niu Technologies (NIU) – -4.72%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers RQi, NQi, MQi, SQi, UQi, and Gova series electric scooters and motorcycles; KQi series one kick-scooters; BQi series e-bikes; and Niu Aero Sports Bicycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, smart check, and smart services, as well as NIU cover, which provides insurance services. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies dropping 4.72% to $2.22 on Friday while NASDAQ rose 1.37% to $14,339.99.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.94%.

Yearly Top and Bottom Value

Niu Technologies’s stock is valued at $2.22 at 01:32 EST, way below its 52-week high of $6.19 and way higher than its 52-week low of $1.94.

Moving Average

Niu Technologies’s worth is under its 50-day moving average of $2.39 and way under its 200-day moving average of $3.44.

Sales Growth

Niu Technologies’s sales growth for the current quarter is 913.7%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Niu Technologies’s EBITDA is 0.02.

More news about Niu Technologies.

Stay up to date with our winners and losers daily report